"Adenosine Monophosphate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
| Descriptor ID |
D000249
|
| MeSH Number(s) |
D03.633.100.759.646.138.180 D13.695.667.138.180 D13.695.827.068.180
|
| Concept/Terms |
2'-Adenylic Acid- 2'-Adenylic Acid
- 2' Adenylic Acid
- Acid, 2'-Adenylic
- 2'-Adenosine Monophosphate
- 2' Adenosine Monophosphate
- Monophosphate, 2'-Adenosine
- Adenylic Acid
- 2'-AMP
|
Below are MeSH descriptors whose meaning is more general than "Adenosine Monophosphate".
Below are MeSH descriptors whose meaning is more specific than "Adenosine Monophosphate".
This graph shows the total number of publications written about "Adenosine Monophosphate" by people in this website by year, and whether "Adenosine Monophosphate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 5 | 7 |
| 2021 | 2 | 2 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 1 | 3 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenosine Monophosphate" by people in Profiles.
-
Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022-2023: A nationwide claims-based cohort study in Japan. J Infect Chemother. 2025 Nov; 31(11):102830.
-
Maintenance therapy with a P2Y12 receptor inhibitor after cangrelor in patients with acute coronary syndrome. The ELECTRA-SIRIO 2 investigators' viewpoint. Cardiol J. 2025; 32(1):83-89.
-
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir. J Infect Dis. 2024 Sep 23; 230(3):624-634.
-
Remdesivir for COVID-19 in Hospitalized Children: A Phase 2/3 Study. Pediatrics. 2024 Mar 01; 153(3).
-
Propensity score matched analysis for the safety and effectiveness of remdesivir in COVID-19 patients with renal impairment. BMC Infect Dis. 2024 Jan 02; 24(1):3.
-
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023 09; 11(9):791-803.
-
Treatment of Severe COVID-19 Infection With Remdesivir in Peritoneal Dialysis. J Investig Med High Impact Case Rep. 2023 Jan-Dec; 11:23247096231200386.
-
Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Ann Intern Med. 2022 12; 175(12):1716-1727.
-
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial. Ann Intern Med. 2022 02; 175(2):234-243.
-
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 12; 9(12):1365-1376.